Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASAH1 | Q13510 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.38 |
| ▸ | RECQL | P46063 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.34 |
| ▸ | KMO | O15229 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30376517 | 0.91 | ASAH1 (0.42) | ASAH1SLC6A2RECQLCYP1A2POLB | |
| SCHEMBL22810558 | 0.87 | ASAH1 (0.44) | ASAH1SLC6A2RECQLCYP1A2POLB | |
| SCHEMBL21311151 | 0.79 | ASAH1 (0.45) | ASAH1SLC6A2RECQLCYP1A2POLB | |
| SCHEMBL22810539 | 0.76 | SLC6A2 (0.40) | ASAH1SLC6A2RECQLCYP1A2POLB | |
| SCHEMBL3862440 | 0.76 | RECQL (0.42) | ASAH1SLC6A2RECQLCYP1A2POLB | |
| SCHEMBL30833682 | 0.75 | KMO (0.33) | ASAH1POLBTLR8KMOSMN1; SMN2 | |
| SCHEMBL5365405 | 0.75 | POLB (0.41) | ASAH1SLC6A2RECQLCYP1A2POLB | |
| SCHEMBL5335838 | 0.74 | HDAC8 (0.42) | SLC6A2RECQLKMOSMN1; SMN2LMNA | |
| SCHEMBL21591511 | 0.74 | RECQL (0.41) | ASAH1SLC6A2RECQLCYP1A2POLB | |
| SCHEMBL27722606 | 0.72 | POLB (0.39) | ASAH1SLC6A2RECQLCYP1A2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190262371-A1 | METHODS AND COMPOSITION FOR THE TREATMENT OF RNA VIRAL INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-08-29 | — | — | US | disclosed |
| WO-2018093968-A1 | IMIDAZOPYRIDAZINE MODULATORS OF IL-12, IL-23 AND/OR IFN-ALPHA | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190262371-A1 | METHODS AND COMPOSITION FOR THE TREATMENT OF RNA VIRAL INFECTIONS | POLRMT, EIF2AK2, NSUN3 | ASAH1 399/4885SLC6A2 4251/4885RECQL 699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.